An ancestor of the Chinese hamster ovary cell lines used for production of recombinant therapeutics has been sequenced.
References
Xu, X. et al. Nat. Biotechnol. 29, 735–741 (2011).
Puck, T.T., Cieciura, S.J. & Robinson, A. J. Exp. Med. 108, 945–956 (1958).
Urlaub, G. & Chasin, L. Proc. Natl. Acad. Sci. USA 77, 4216–4220 (1980).
Urlaub, G., Käs, E., Carothers, A.M. & Chasin, L.A. Cell 33, 405–412 (1983).
Wurm, F.M. et al. Methotrexate and CHO cells: productivity and genetics of amplified expression vector sequences. in Production of Biologicals from Animal Cells in Culture (eds. Spier, R.E., Griffiths, J.B. & Meignier, B.) 316–326 (Butterworths, Oxford, 1990).
Deaven, L.L. & Petersen, D.F. Chromosoma 41, 129–144 (1973).
Kao, F.-T. & Puck, T.T. Nature 228, 329–332 (1970).
Derouazi, M. et al. Biochem. Biophys. Res. Commun. 340, 1069–1077 (2006).
Hsu, T.C. Int. Rev. Cytol. 12, 69–161 (1961).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Wurm, F., Hacker, D. First CHO genome. Nat Biotechnol 29, 718–720 (2011). https://doi.org/10.1038/nbt.1943
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1943
- Springer Nature America, Inc.
This article is cited by
-
A comprehensive evaluation of stable expression “hot spot” in the ScltI gene of Chinese hamster ovary cells
Applied Microbiology and Biotechnology (2023)
-
Chinese Hamster Ovary Cell Line Instability: Causes, Mitigation, and Prediction
Biotechnology and Bioprocess Engineering (2023)
-
Construction of a CHO cell line with site-specific integration to stably express exogenous proteins using the CRISPR–Cas9 technique
Systems Microbiology and Biomanufacturing (2023)
-
Introducing oxygen transfer rate measurements as a novel method for time-resolved cytotoxicity assessment in shake flasks
Environmental Sciences Europe (2022)
-
Development of a CHO cell line for stable production of recombinant antibodies against human MMP9
BMC Biotechnology (2022)